Les combinaisons de Trodelvy et HER-2 TriNKET seront utilisées dans le cancer du sein métastatique et le cancer du poumon non à petites cellules (CPNPC). WALTHAM, Massachusetts, 15 février 2024 /PRNewswire/ — Dragonfly Therapeutics, Inc., une société de biotechnologie au stade clinique…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.